Show simple item record

dc.contributor.authorPal, A
dc.contributor.authorStapleton, S
dc.contributor.authorYap, C
dc.contributor.authorLai-Kwon, J
dc.contributor.authorDaly, R
dc.contributor.authorMagkos, D
dc.contributor.authorBaikady, BR
dc.contributor.authorMinchom, A
dc.contributor.authorBanerji, U
dc.contributor.authorDe Bono, J
dc.contributor.authorKarikios, D
dc.contributor.authorBoyle, F
dc.contributor.authorLopez, J
dc.identifier.citationBMJ Open, 2021, 11 (9), pp. e049217 - e049217en_US
dc.description.abstract<jats:sec><jats:title>Introduction</jats:title><jats:p>Early phase cancer clinical trials have become increasingly complicated in terms of patient selection and trial procedures—this is reflected in the increasing length of participant information sheets (PIS). Informed consent for early phase clinical trials has been contentious due to the potential ethical issues associated with performing experimental research on a terminally ill population which has exhausted standard treatment options. Empirical studies have demonstrated significant gaps in patient understanding regarding the nature and intent of these trials. This study aims to test whether enhanced informed consent for patient education can improve patient scores on a validated questionnaire testing clinical trial comprehension.</jats:p></jats:sec><jats:sec><jats:title>Methods and analysis</jats:title><jats:p>This is a randomised controlled trial that will allocate patients who are eligible to participate in one of four investigator-initiated clinical trials at the Royal Marsden Drug Development Unit to either a standard arm or an experimental arm, stratified by age and educational level. The standard arm will involve the full length trial PIS, followed by electronic or paper administration of the Quality of Informed Consent Questionnaire Parts A and B (QuIC-A and QuIC-B). The experimental arm will involve the full length trial PIS, exposure to a two-page study aid and 10 online educational videos, followed by administration of the QuIC-A and QuIC-B. The primary endpoint will be the difference (using a one-sided two-sample t-test) in the QuIC-A score, which measures objective understanding, between the standard and experimental arm. Accrual target is at least 17 patients per arm to detect an 8 point difference (80% power, alpha 0.05).</jats:p></jats:sec><jats:sec><jats:title>Ethics and dissemination</jats:title><jats:p>Ethics approval was granted by the National Health Service Health Research Authority on 15 June 2020—IRAS Project ID 277065, Protocol Number CCR5165, REC Reference 20/EE/0155. Results will be disseminated via publication in a relevant journal.</jats:p></jats:sec><jats:sec><jats:title>Trial registration number</jats:title><jats:p><jats:ext-link xmlns:xlink="" ext-link-type="clintrialgov" specific-use="clinicaltrial pre-results" xlink:href="NCT04407676">NCT04407676</jats:ext-link>; Pre-results.</jats:p></jats:sec>en_US
dc.format.extente049217 - e049217en_US
dc.titleStudy protocol for a randomised controlled trial of enhanced informed consent compared to standard informed consent to improve patient understanding of early phase oncology clinical trials (CONSENT)en_US
dc.typeJournal Article
dc.relation.isPartOfBMJ Openen_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Trials & Statistics Unit
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/The Adult Drug Development Unit at the ICR and the RM
pubs.embargo.termsNot knownen_US
icr.researchteamClinical Trials & Statistics Unit
icr.researchteamThe Adult Drug Development Unit at the ICR and the RM
dc.contributor.icrauthorYap, Christinaen_US
dc.contributor.icrauthorMinchom, Annaen_US

Files in this item


This item appears in the following Collection(s)

Show simple item record
Except where otherwise noted, this item's license is described as